Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Katherine K. Matthay

Pediatrics | Hematology
505 Parnassus Ave, 
San Francisco, CA 
Elite in Embryonal Tumor with Multilayered Rosettes
505 Parnassus Ave, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Katherine Matthay is a Pediatrics specialist and a Hematologist in San Francisco, California. Dr. Matthay is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Infantile Neutropenia, Thrombocytopenia, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 136 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 110 articles and participated in 9 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties
Pediatrics
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

505 Parnassus Ave, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Dinutuximab, Isotretinoin, Lenalidomide
Study Phase: Phase 1
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Enrollment Status: Available
Publish Date: July 22, 2025
Intervention Type: Drug
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
A Phase 1 Study of Selinexor (KPT-330), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Other
Study Drug: Selinexor
Study Phase: Phase 1
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
A Phase 1 Study of Crizotinib in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 05, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma
Enrollment Status: Completed
Publish Date: October 13, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 26, 2023
Intervention Type: Drug
Study Drugs: Adavosertib, Irinotecan Hydrochloride
Study Phase: Phase 1/Phase 2
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Dinutuximab, Irinotecan Hydrochloride, Sargramostim, Temozolomide, Temsirolimus
Study Phase: Phase 2
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Drug
Study Phase: Phase 1
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
Enrollment Status: Terminated
Publish Date: May 14, 2021
Intervention Type: Drug, Procedure
Study Phase: Early Phase 1
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies
Enrollment Status: Completed
Publish Date: March 26, 2021
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma
Enrollment Status: Terminated
Publish Date: April 16, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

141 Total Publications

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025
Similar Doctors
Elite in Embryonal Tumor with Multilayered Rosettes
Dr. Louis Chesler
Pediatrics
Elite in Embryonal Tumor with Multilayered Rosettes
Dr. Louis Chesler
Pediatrics
400 Parnassus Ave, 
San Francisco, CA 
 (0.1 miles away)
415-476-3831
Languages Spoken:
English

Louis Chesler is a Pediatrics provider in San Francisco, California. Dr. Chesler is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Delayed Growth, and Tissue Biopsy.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sonia Partap
Pediatric Neurology | Pediatrics | Neurology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Sonia Partap
Pediatric Neurology | Pediatrics | Neurology
725 Welch Rd, 
Palo Alto, CA 
 (27.4 miles away)
650-497-8000
Languages Spoken:
English
See accepted insurances

Sonia Partap is a Pediatric Neurologist and a Pediatrics provider in Palo Alto, California. Dr. Partap is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Medulloblastoma, Glioma, Embryonal Tumor with Multilayered Rosettes, and Posterior Fossa Tumor.

Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Gigi Q. Chen
Hematology Oncology | Hematology | Oncology
Distinguished in Embryonal Tumor with Multilayered Rosettes
Dr. Gigi Q. Chen
Hematology Oncology | Hematology | Oncology

John Muir Physician Network

1914 Tice Valley Blvd, 
Walnut Creek, CA 
 (22.4 miles away)
925-988-7595
Languages Spoken:
English, Bulgarian, Farsi, Filipino, French, Mandarin, Spanish
See accepted insurances
Offers Telehealth

Gigi Chen is a Hematologist Oncology specialist and a Hematologist in Walnut Creek, California. Dr. Chen is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Lung Cancer, Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, and Neuroepithelioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matthay's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile